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Thoracic aortic aneurysm, as occurs in Marfan syndrome, is generally asymptomatic until
dissection or rupture, requiring surgical intervention as the only available treatment. Here, we
show that nitric oxide (NO) signaling dysregulates actin cytoskeleton dynamics in Marfan
Syndrome smooth muscle cells and that NO-donors induce Marfan-like aortopathy in wild-
type mice, indicating that a marked increase in NO suffices to induce aortopathy. Levels of
nitrated proteins are higher in plasma from Marfan patients and mice and in aortic tissue
from Marfan mice than in control samples, indicating elevated circulating and tissue NO.
Soluble guanylate cyclase and cGMP-dependent protein kinase are both activated in Marfan
patients and mice and in wild-type mice treated with NO-donors, as shown by increased
plasma cGMP and pVASP-S239 staining in aortic tissue. Marfan aortopathy in mice is
reverted by pharmacological inhibition of soluble guanylate cyclase and cGMP-dependent
protein kinase and lentiviral-mediated Prkg1 silencing. These findings identify potential bio-
markers for monitoring Marfan Syndrome in patients and urge evaluation of cGMP-
dependent protein kinase and soluble guanylate cyclase as therapeutic targets.
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Thoracic aortic aneurysm and dissection (TAAD) is a majorcause of morbidity and mortality in developed countries1.TAAD is characterized by progressive vessel dilation
associated with vascular smooth muscle cell (VSMC) dysfunction
and destructive extracellular matrix remodeling2,3. TAAD is often
asymptomatic until the aorta dissects or ruptures. Approximately
one in four cases of TAAD have a known genetic basis and can be
categorized as either syndromic (showing prominent phenotypic
features of a systemic connective tissue disorder such as Marfan
syndrome [MFS]) or nonsyndromic, with an essentially vascular
phenotype3. TAAD and rupture account for >90% of MFS patient
deaths4,5. MFS is an inherited autosomal dominant disease caused
by pathogenic variants of the fibrillin-1-encoding gene FBN1.
Fibrillin-1 is a major component of extracellular microfibrils,
providing a scaffold for elastic-fiber formation and maturation6.
Mutant fibrillin-1 disrupts microfibril formation, leading to
medial degeneration, which destabilizes the aortic wall, rendering
the aorta vulnerable to hemodynamic injury7,8. Medial degen-
eration is characterized by poor alignment of elastin filaments,
disorganization of lamellar units, VSMC death, and proteoglycan
accumulation9. Proteoglycans play essential roles in the pre-
servation of aortic structure and function by regulating elastic
fiber assembly and smooth muscle cell proliferation10–12.
Current therapy for the cardiovascular complications of MFS
consists of strict follow-up, life-style advice, medical treatment to
slow the rate of aortic root dilation, and surgery to prevent dis-
section or rupture13. Pharmacological therapy is usually based on
ß-adrenoceptor blockade14. However, this treatment neither halts
abnormal aortic growth nor prevents aortic dissection or death14.
Moreover, some studies suggest that ß-adrenergic blockers do not
even slow the rate of aortic growth in MFS15,16. There is therefore
a need for effective pharmacological strategies to manage TAAD
in MFS patients.
MFS is accompanied by impaired aortic contractility17, caused
by as yet unknown molecular mechanisms. In small arteries,
VSMC relaxation and vasodilatation are induced by nitric oxide
(NO), produced in endothelial cells by constitutively expressed
endothelial NO synthase (eNOS; also called NOS3). NO can also
be produced by constitutively expressed NOS of neuronal origin
(nNOS; also called NOS1) or by inducible NOS (iNOS; also called
NOS2)18. NOS2 expression is induced in MFS patients and in a
mouse model of MFS, and TAAD is reversed in the mouse model
by pharmacological NOS2 inhibitors, raising the possibility that
blocking NOS2 activity could be a promising treatment for
TAAD19. However, the mechanisms by which NOS2 contributes
to TAAD in MFS remain unclear. Increased NOS2-derived NO
levels stimulate soluble guanylate cyclase (sGC) to generate
cGMP, which in turn activates cGMP-dependent protein
kinase G (PRKG), which modulates the contractility of resistance
vessels by regulating actin filament and myosin dynamics20.
NO also regulates numerous physiological processes in a
cGMP-independent manner, including mechanisms based on
S-nitrosylation21,22 and, in the presence or excess reactive oxygen
species (ROS), protein tyrosine nitration23.
In response to limited availability of the substrate L-arginine or
the cofactor tetrahydrobiopterin (BH4)24–26, or high ROS
levels27, all NOS enzymes generate superoxide anion instead of
NO, resulting in oxidative stress. As ROS levels are elevated in the
MFS aorta17,28, NOS2 might be responsible for superoxide anion
generation in this scenario. Moreover, ROS activate PRKG by
direct oxidation29, raising questions about whether TAAD gen-
eration in MFS is mediated by NOS2-derived superoxide or NO
and whether cGMP or PRKG act as regulators in this process.
Here, we show that the NO–sGC–PRKG signaling pathway is
activated in MFS mice and MFS patients, and demonstrate that
this pathway mediates aortopathy in a mouse model of MFS.
Results
NO signaling pathway activation dysregulates actin cytoskele-
ton dynamics in MFS VSMCs. To investigate whether the
NO–sGC–PRKG signaling pathway is activated in MFS, we
measured VASP-S239 phosphorylation (pVASP-S239) as a
readout of PRKG activity30 in primary aortic VSMCs from wild-
type (WT) mice31,32 and a mouse model of MFS (Fbn1C1039G/+
mice)33 cultured in the presence of inhibitors of NOS (L-NAME),
sGC (ODQ), and PRKG (KT5823) (Fig. 1a). As pathway activa-
tion controls, we also treated WT cells with the cGMP analog 8-
Br-cGMP or the NO-donor DetaNONOate (DetaNO). These
agents induced pVASP-S239, and this event was prevented by the
corresponding inhibitors ODQ and KT5823 (Fig. 1b, c).
Untreated MFS VSMCs had higher pVASP-S239 levels than
WT cells (Fig. 1b, c), and these levels were sharply decreased by
treatment with ODQ or KT5823 (Fig. 1b, c), strongly suggesting
that the NO–sGC–PRKG signaling pathway is activated in MFS
VSMCs.
VASP-S239 phosphorylation impairs actin filament
formation34,35, and we therefore investigated whether pVASP-
S239 regulation by the NO–sGC–PRKG signaling pathway
negatively correlated with actin filament formation. Phalloidin
staining showed a sharp decrease of filamentous actin (F-actin)
accumulation in WT VSMCs treated with DetaNO or 8-Br-
cGMP, correlating with low F-actin in untreated MFS cells
(Fig. 2a, b). Moreover, PRKG inhibition by KT5823 in MFS
VSMCs markedly increased F-actin formation to levels similar to
those found in control cells (Fig. 2b), supporting the notion that
the NO signaling pathway is critical for actin cytoskeleton
dynamics regulation in MFS.
Regulation of actin cytoskeleton dynamics is critical for
effective cell contraction; moreover, the expression of contractile
protein markers, including alpha-smooth muscle actin (Acta2),
smooth muscle protein 22 alpha (Tagln2), and calponin-1
(Cnn1), is increased in the aorta of MFS mice relative to WT
mice36. Given these observations, we assessed the role of the
NO–sGC–PRKG pathway in regulating the expression of these
markers. RT-qPCR analysis showed a substantial increase in
Acta2, Cnn1, and Tagln2 mRNA in WT VSMCs treated with
DetaNO or 8-Br-cGMP (Fig. 2c) and also in MFS VSMCs
(Fig. 2d). Consistent with a role for the NO pathway in regulating
the expression of these markers, pharmacological PRKG
inhibition decreased their expression to normal levels (Fig. 2d).
These results indicate that some of the enhanced SMC markers
characteristic of MFS VSMCs can be reverted by NO–sGC–PRKG
targeting.
MFS smooth muscle cells harboring the FBN1C1242Y patho-
genic variant show defective deposition of fibrillin-137. However,
we found no notable effect on extracellular fibrillin-1 deposition
in WT VSMCs treated with with 8-Br-cGMP (Supplementary
Fig. 1).
Together these results strongly suggest that overactivation of
the NO–sGC–PRKG pathway in MFS VSMCs switches their
phenotype by dysregulating the contractile machinery, including
actin cytoskeleton dynamics, without affecting microfibril
formation.
Supraphysiological NO levels induce an MFS-like aortic
pathology. VSMCs from MFS patients and the Fbn1C1039G/+
mouse model (MFS mice) express high levels of NOS219, a NOS
enzyme that produces large amounts of NO38. We therefore
investigated whether supraphysiological NO levels affect aortic
homeostasis in healthy mice. As an NO source, we used iso-
sorbide mononitrate (ISMN), a long-lasting nitrate that is meta-
bolized to NO within VSMCs and induces dilation of systemic
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Fig. 1 Pharmacological inhibition of signaling components of the NO–sGC–PRKG pathway decreases pVASP-S239 induction in VSMCs from MFS mice.
a NO signaling components and the targets of pharmacological stimuli (green) and inhibitors (red). b Representative images of pVASP-S239
immunofluorescence (red) and DAPI-stained nuclei (blue). c Quantification of pVASP-S239 immunofluorescence in WT and MFS VSMCs treated with
300 µM L-NAME, 10 µMODQ, or 1 µM KT5823 for 1 h before stimulation for 5 minutes with 100 µM 8-Br-cGMP or 100 µMDetaNO, as indicated. b, c Five
independent cell batches were used for all conditions except for MFS VSMCs (n= 4). Scale bar, 50 μm. Data are shown relative to untreated WT cells as
mean ± s.e.m. Each data point denotes the mean value from an independent experiment. Differences were analyzed by one‐way ANOVA with Dunnett’s
post-hoc test (p-values are shown). Source data are provided in the Source Data file.
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and coronary vascular beds39. We performed in vivo longitudinal
dose-response studies to characterize the effects of infusing ISMN
for 7 days on the aortic phenotype of WT C57BL/6 mice (Fig. 3a).
Since there were no previous reports on the effect of ISMN on
aortic phenotype, and the normal clinical dose of ISMN used to
treat chronic stable angina pectoris ranges from 0.5 to 4 mg/kg/
day, we tested several doses from 1 to 50 mg/kg/day. ISMN
induced a dose-dependent decrease in systolic blood pressure
(BP) (Fig. 3b) and dilation of both the ascending aorta (AsAo)
and the abdominal aorta (AbAo) (Fig. 3c, d). Aortic diameters at
the highest dose were similar to those in MFS mice (Fig. 3e).
ISMN doses above 50 mg/kg/day did not induce larger aortic
dilations or BP drops (Supplementary Fig. 2), and this dose was
therefore used for further experiments.
Fig. 2 The NO–sGC–PRKG pathway modulates the contractility phenotype of VSMCs. a, b Representative images of F-actin staining (red) and DAPI-
stained nuclei (blue) and F-actin quantification in aWT VSMCs treated as indicated for 5 min (n= 4 independent cell batches per condition) and bWT and
MFS VSMCs untreated or treated with KT5823 for 24 h (n= 5 independent cell batches per condition). Scale bar, 50 μm. Data are shown relative to
untreated WT cells as mean ± s.e.m. Each data point denotes the mean value from an independent experiment. Differences were analyzed by one‐way
ANOVA with Tukey’s post-hoc test (p-values are shown). c, d RT-qPCR analysis of Acta2, Cnn1, and Tagln2 mRNA expression in c WT VSMCs treated as
indicated for 4 h and d WT or MFS VSMCs treated as indicated for 24 h (n= 4 independent cell batches per group in c and n= 5 independent cell batches
per group in d). mRNA amounts were normalized to Gapdh expression (mean ± s.e.m.). Each data point denotes the mean value from an independent
experiment. Differences were analyzed by one‐way ANOVA followed by Dunnett’s post-hoc test (p-values are shown). Source data are provided in the
Source Data file.
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To determine if other NO donors had a similar effect on BP
and aortic dilation, we treated WT mice with DetaNO. Unlike
ISMN, DetaNO is unstable at 37 °C, and we therefore used
osmotic minipumps to infuse it for just 2 days. Like ISMN,
DetaNO decreased systolic BP (Supplementary Fig. 3a) and
induced marked AsAo and AbAo dilations (Supplementary
Fig. 3b-c).
FBN1 pathogenic variants cause not only aortic dilation, but
also medial degeneration characterized by elastic-fiber fragmen-
tation and disarray and proteoglycan accumulation in the aorta, a
feature that might predispose to dissection10. Histological analysis
of the AsAo40 in ISMN-infused WT mice revealed both
proteoglycan accumulation and elastic-fiber fragmentation and
disorganization as early as 7 days after treatment initiation, as
shown by Alcian Blue and modified Verhoeff elastic-Van Gieson
(EVG) staining, respectively (Fig. 3f, g). After 28 days, these
features were more pronounced and were comparable to those in
age-matched MFS mice (Fig. 3f, g). Similar elastic-fiber alterations
were found upon treatment of WT mice with DetaNO
(Supplementary Fig. 3d-3e). These results thus indicate that
supraphysiological levels of NO are sufficient to induce MFS-like
aortopathy in WT mice.
In humans, sustained high plasma nitrate concentrations
induce a clinically relevant decay of the vasodilatory effect,
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-22933-3 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:2628 | https://doi.org/10.1038/s41467-021-22933-3 | www.nature.com/naturecommunications 5
known as nitrate tolerance41. To investigate if continuous ISMN
delivery in mice loses efficacy over the long term, we performed a
longitudinal study in which ISMN (50 mg/kg/day) was infused for
28 days (Supplementary Fig. 4a). In line with the results shown in
Fig. 3, ISMN sharply decreased systolic BP and increased AsAo
and AbAo diameters after 1 day of infusion; moreover, these
effects were sustained over the remaining days of treatment
(Supplementary Fig. 4b-4c), ruling out a tolerance phenomenon.
The sGC–PRKG signaling pathway is activated in MFS mice
and patients. We next investigated whether the elevated NOS2
expression found in MFS patients and mice results in activation
of the sGC–PRKG signaling pathway. sGC generates cGMP, and
intracellular cGMP pools are in a dynamic steady-state relation-
ship with plasma cGMP levels42,43. We found substantially ele-
vated plasma cGMP in both MFS mice and ISMN-treated WT
mice (Fig. 4a), strongly suggesting that sGC is indeed activated in
MFS mice. Similar plasma cGMP increases were found upon
DetaNO treatment (Fig. 4b). As a readout of PRKG activity, we
determined pVASP-S239 levels in aortic tissue. pVASP-S239
levels were very high in the aortas of MFS mice or WT mice
treated with ISMN for 7 or 28 days (Fig. 4c, d and Supplementary
Fig. 5). The increase in plasma cGMP and aortic pVASP-S239
was not due to increased sGC or Prkg mRNA or protein
expression in MFS (Supplementary Fig. 6), suggesting that sGC
and Prkg are activated in MFS by post-translational mechanisms.
To determine if the NO–sGC–PRKG pathway is activated in
MFS patients, we measured serum or plasma cGMP and PRKG
activity in aortic tissue from MFS patients. Plasma or serum
cGMP from three independent MFS patient cohorts was
markedly higher than in healthy donors (Fig. 5a). PRKG activity
was also higher in aortic sections from two MFS patient cohorts
than in sections from multiorgan transplant donors. Immuno-
histochemistry and immunofluorescence revealed higher pVASP-
S239 levels in MFS samples (Fig. 5b, c and Supplementary Fig. 7).
Together, these data strongly suggest that the sGC–PRKG
pathway is activated in MFS patients.
MFS mice and patients have elevated levels of protein nitration
in aortic tissue and plasma. The lipophilic properties of NO
allow it to diffuse from the vessel wall to the vessel lumen23,44,
where it can potentially trigger NO-derived modifications of
plasma proteins. These include Cys S-nitrosylation, a labile
modification that cannot be directly detected unless a stable
derivative is generated45, and nitration, a stable modification that
takes place under pro-oxidant conditions46. We carried out a
high-throughput proteomics analysis to explore the relative
nitration levels of plasma proteins in seven MFS mice and seven
WT littermates. As a positive control, we also included 6
DetaNO-treated WT mice. Mass spectrometry analysis of plasma
protein digests quantified 43 nitrated peptide species identified in
more than 1 MS/MS spectrum from 19 nitrated proteins that
included 47 nitrated sites (NS) (Supplementary Data 1 and 2). Of
the NS, 88% correspond to nitro-Tyr and 12% to nitro-Trp.
The cumulative distribution of nitro-protein quantifications in
plasma from NO-donor-treated mice was significantly shifted
toward positive values in relation to other plasma proteins
(Fig. 6a), indicating that NO treatment produced a generalized
increase in nitrated protein abundance. In contrast, the cumula-
tive distribution of all remaining plasma proteins closely
followed the expected null-hypothesis distribution (Fig. 6a),
demonstrating the accuracy of the model and that the nitration
profile was not biased due to the quantitative analysis applied.
Interestingly, the relative abundance of nitrated proteins was also
elevated in plasma from MFS mice (Fig. 6a), demonstrating
an increased nitration in these mice that can be clearly detected
in plasma.
To determine if increased aortic NO levels in MFS patients is
also indicated by elevated plasma-protein nitration, we performed
a quantitative proteomics analysis in plasma samples from 30
healthy donors and 23 MFS patients, identifying 40 nitrated
peptide species from 18 nitrated proteins, many of which were
also found in the analysis of mouse plasma (Supplementary
Data 3 and 4). Among 43 NS identified in these peptides, 66%
correspond to nitro-Tyr and 34% to nitro-Trp. Reproducing the
results obtained in mice, plasma from MFS patients showed a
generalized elevation in the abundance of nitrated proteins
relative to controls (Fig. 6b), suggesting that a highly nitrated
plasma profile may be a signature of MFS and strongly
supporting the notion that NO levels are increased in MFS. To
provide a set of candidate nitrated peptides as biomarkers for
clinical diagnosis or prognosis, we selected the nitrated peptides
that were significantly upregulated in MFS patients (Fig. 6c). The
quantitative values of these peptides were combined to obtain a
nitrated plasma index (NPI), which provides a measure of the
increase in nitration. Mean NPI was clearly increased in the MFS
population, with most MFS patients remaining above the mean of
the healthy controls (Fig. 6d).
We additionally searched for aortic tissue proteins whose
nitration levels could be affected by NO–sGC–PRKG pathway
activation. Quantitative proteomics analysis in pooled aorta
samples from 12 WT (n = 6 pools) and 12 MFS (n = 6 pools)
mice identified 124 nitrated peptide species from 104 nitro-
proteins, which included 147 NS (Supplementary Data 5). Of
these NS, 75% correspond to nitro-Tyr and 25% to nitro-Trp.
MFS mice showed a consistent and significant upregulation of 24
aortic nitro-proteins (Fig. 6e and Supplementary Fig. 8). This
analysis revealed a sharp increase of Acta2 nitration as well as
substantial increases in the nitration of seven additional
Fig. 3 ISMN induces an MFS-like aortopathy in WT mice. a Experimental design. 12-week-old C57BL/6 mice were treated for 7 days (d) with the NO-
donor ISMN at 1, 2.5, 5, 10, 25, or 50 mg/kg/day by osmotic minipump infusion. Mice were monitored by Eco-BP (ultrasound and BP analysis) at the
indicated times (empty triangles). b Systolic BP during ISMN infusion. c Maximal AsAo diameter (left) and AbAo diameter (right) during ISMN infusion.
Data in b and c are mean ± s.e.m; n= 5 per treated group, n= 3 for control group. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 (versus control at
each time point) by repeated-measurements two-way ANOVA with Bonferroni’s post-hoc test. d Representative ultrasound images (orange dashed lines
delineate the lumen boundary and yellow dashed lines mark the lumen diameter) and e quantification of end-of-experiment maximal AsAo and AbAo
diameter in untreated WT mice (−) (n= 8), MFS mice (n= 7), and WT mice treated with 50mg/kg/day ISMN for 7 d (n= 5). Each data point denotes an
individual mouse, whereas histograms show mean ± s.e.m. f Representative staining with hematoxylin and eosin (HE) (left), Alcian blue (middle), and
elastic van Gieson (EVG) (right) in the AsAo from 9 to 12-week-old untreated WT mice (−), 6 MFS mice, and WT mice treated with 50mg/kg/day ISMN
for 7 d (n= 12 mice) or 28 d (n= 6 mice). Yellow arrowheads indicate elastin breaks. Scale bar, 50 μm. g Quantification of elastin breaks in AsAo sections
from 9 to 12-week-old untreated WT mice (−), 6 MFS mice, and WT mice treated with 50mg/kg/day ISMN for 7 d (n= 12 mice) or 28 d (n= 6 mice).
Each data point denotes an individual mouse, whereas histograms denote mean ± s.e.m. e, g Differences were analyzed by one-way ANOVA with
Dunnett’s post-hoc test (p-values are shown). Source data are provided in the Source Data file.
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cytoskeletal and extracellular matrix proteins that might play a
role in contractility regulation (Fig. 6f).
The NO–sGC–PRKG pathway mediates aortopathy in MFS.
Activation of the NO–sGC–PRKG signaling pathway in MFS
patients and mice suggested its involvement in MFS aortopathy.
However, increased plasma-protein nitration in MFS patients and
mice is also consistent with a cGMP-independent contribution of
NO to aortic disease. To ascertain whether sGC–PRKG activation
plays a causal role in MFS aortopathy, we treated MFS mice with
pharmacological inhibitors of these enzymes. Daily intraper-
itoneal (i.p.) administration of the sGC inhibitor ODQ (20 mg/
kg/day) to 14-week-old MFS mice (Fig. 7a) markedly decreased
plasma cGMP (Fig. 7b), inhibited Prkg activity determined by
pVASP-S239 aortic staining (Fig. 7c, d), and completely reversed
AsAo and AbAo dilation after 7 days without inducing arterial
hypertension (Fig. 7e, f). Histological analysis of AsAo cross-
sections after 21 days of treatment showed that pharmacological
sGC inhibition partially reverted elastic-fiber fragmentation and
decreased aortic wall thickness (Supplementary Fig. 11).
Daily i.p. treatment of MFS mice with the PRKG inhibitor
KT5823 (2 µmol/kg/day) (Fig. 7g) had similar effects on Prkg
activity (Fig. 7h, i), AsAo and AbAo dilation, and BP (Fig. 7j, k),
suggesting that sGC and PRKG mediate aortic disease in MFS.
However, no reversion of medial degeneration was observed after
7 days of KT5823 treatment (Supplementary Fig. 11a), suggesting
that tissue regeneration might require a longer period of Prkg
suppression.
To test this hypothesis, we silenced Prkg expression in the aortas
of adult MFS mice. There are 2 Prkg isoforms: Prkg1, which is
ubiquitously expressed but particularly abundant in vascular
smooth muscle cells; and Prkg2, which is mainly expressed in
non-vascular tissues47. We therefore screened candidate shRNAs
specific for Prkg1 in cultured VSMCs, identifying shPrkg1-A and
shPrkg1-B as having high silencing capacity (Fig. 8a). The shRNA-
encoding lentivirus also encoded green fluorescent protein (GFP) to
facilitate assessment of transduction efficiency48,49. In vitro
transduction of MFS VSMCs with control shRNA (shScr),
shPrkg1-A, or shPrkg1-B lentivirus yielded similar GFP mRNA
expression levels, and Prkg1 expression was specifically silenced by
shPrkg1-A and shPrkg1-B lentiviruses (Supplementary Fig. 12a).
Fig. 4 The sGC–PRKG pathway is activated in MFS and in NO-donor-treated mice. a Plasma cGMP in 12–13-week-old untreated WT mice (−) (n= 14),
MFS mice (n= 13), and WT mice treated with 50mg/kg/day ISMN for 7 d (n= 20). b Plasma cGMP in untreated WT mice (Control) (n= 4) and WT
mice treated with 5mg/kg/day DetaNO for 2 d (n= 10). c Representative images of pVASP-S239 immunofluorescence (red), elastin autofluorescence
(green), and DAPI-stained nuclei (blue). d Quantification of pVASP-S239 immunofluorescence in aortic sections from 12-week-old untreated WT mice (−)
(n= 9), MFS mice (n= 9), and WT mice treated with 50 mg/kg/day ISMN for 7 d (n= 10) or 28 d (n= 5). IgG staining served as a negative control. Scale
bar, 50 µm. a, b, d Data are shown relative to untreated WT mice as mean ± s.e.m. Data points denote individual mice. Differences were analyzed by a, d
one-way ANOVA with Dunnett’s post-hoc test or b unpaired two-tailed t-test (p-values are shown). Source data are provided in the Source Data file.
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Consistent with the results obtained upon pharmacological Prkg
inhibition, Prkg1 knockdown decreased the expression of the
contractility markers Acta2, Tagln2, and Cnn1 in MFS cells to
normal levels (Supplementary Fig. 12a) while increasing actin fiber
formation to normal levels (Supplementary Fig. 12b). Prkg1
knockdown did not, however, restore the capacity of MFS VSMCs
to generate extracellular fibrillin-1 fibers (Supplementary Fig. 12c).
Intrajugular delivery of lentivirus encoding shPrkg1-A or shPrkg1-B
into MFS mice (Fig. 8b) yielded efficient transduction of all aortic
layers, determined by GFP immunostaining of aortic sections
4 weeks after lentivirus delivery (Fig. 8c). Prkg1 protein expression
was almost undetectable in aortic samples from these mice (Fig. 8c,
Fig. 5 The sGC–PRKG pathway is activated in aortas of MFS patients. a Plasma (Cohorts 1 and 2) and serum (Cohort 3) cGMP in three independent
cohorts including 24 healthy donors and 38 MFS patients (Cohort 1); 11 healthy donors and 8 MFS patients (Cohort 2); and 11 healthy donors and 33 MFS
patients (Cohort 3). Data are mean ± s.e.m. Each data point denotes an individual. b Representative medial layer images and quantification of pVASP-S239
immunohistochemistry in aortic cross-sections of human samples from 3 control donors and 9 MFS patients. Scale bar, 50 μm. IgG staining served as a
negative control. Data are shown relative to healthy donors as mean ± s.e.m. Each data point denotes an individual. c Representative medial layer images and
quantification of pVASP-S239 immunofluorescence (red) and DAPI-stained nuclei (blue) in sections from 5 control donors and 11 MFS patients. Scale bars,
50 μm. IgG staining served as a negative control. Data are shown relative to healthy donors as mean ± s.e.m. Each data point denotes an individual. a–c
Differences were analyzed by unpaired two-tailed t-test with Welch’s correction (p-values are shown). Source data are provided in the Source Data file.
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d). Consistent with the results obtained with the PRKG inhibitor,
Prkg1 silencing in the aortas of MFS mice markedly decreased
pVASP-S239 aortic staining (Fig. 8e, f) and reversed AsAo and
AbAo dilation (Fig. 8g). Prkg1 knockdown did not raise BP
above normotensive values in untreated littermate controls (Fig. 8h).
Histological analysis of aortic cross-sections showed that
Prkg1 silencing for 28 days led to an almost complete reversal of
medial degeneration, determined by the thickness of the aortic wall
(Fig. 8i, j) and the regression of elastic-fiber fragmentation
and disarray (Fig. 8i, k). Together, these results urge the
evaluation of sGC and PRKG as potential targets for therapeutic
intervention.
Discussion
Our results demonstrate that the NO–sGC–PRKG signaling
pathway mediates aortopathy in a mouse model of MFS and is
activated in MFS mice and MFS patients. These findings identify
potential targets for intervention in human MFS, as well as cir-
culating activation markers of this pathway that might be useful
for MFS disease monitoring and clinical follow-up.
Our previous work in MFS mice showed that NOS2, whose
expression is induced in VSMCs from MFS mice and patients, is
an important mediator of medial degeneration and aortic dila-
tion, key features of MFS aortopathy that are efficiently reverted
by NOS2 inhibition19. NOS2 activity generates much larger
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amounts of NO than NOS3 or NOS138, and therefore its
induction in VSMCs might lead to the sustained production of
high NO levels. This may in turn activate a number of signaling
pathways, with the major candidate being the sGC–PRKG path-
way. However, NO can also signal through sGC–PRKG-inde-
pendent pathways, including those involving nitrosative stress44.
Our results indicate that supraphysiological NO levels, gener-
ated by administration of ISMN or DetaNO, suffice to trigger an
MFS-like aortopathy in WT mice. These NO donors induce dose-
dependent aortic dilation, elastic-fiber fragmentation, and a drop
in BP, as well as recapitulating the sGC–PRKG signaling activa-
tion seen in MFS. The association of increased NO–sGC–PRKG
signaling with aortopathy warrants consideration of the potential
detrimental effects of drugs in clinical use that elicit chronic sti-
mulation of this pathway. This applies not only to NO donors,
but also to drugs that impair cGMP degradation, including
phosphodiesterase type 5 (PDE5) inhibitors. NO donors have
been extensively used to treat angina pectoris and heart failure,
and PDE5 inhibitors to treat pulmonary hypertension and erectile
dysfunction, with, to our knowledge, no reported pathological
consequences related to aortic homeostasis or dilation. Based on
accumulated clinical experience, we do not anticipate that
patients treated with these agents will develop harmful aortic
dilation. Nevertheless, our results with high NO-donor doses in
mice suggest that these patients may be at risk of mild aortic
dilation. Our results therefore indicate the need of caution with
drugs that chronically activate the NO–sGC–PRKG signaling
pathway, since they may be detrimental to aortic homeostasis.
These drugs include advanced sGC stimulators such as Vericiguat
(BAY 1021189) and Riociguat (BAY 63–2521), the latter having
received FDA approval for pulmonary hypertension and heart
failure50,51, as well as novel short-acting sGC activators that lack
hypotensive side effects, such as TY-55002, a candidate for the
treatment of patients with acute decompensated heart failure52.
Seemingly in conflict with our results, increased NO produc-
tion by constitutively active Nos3 has been reported to exert a
beneficial effect on the aorta in MFS mice53. It should be noted,
however, that NO levels generated by Nos3 are almost 1000-fold
lower than those generated by Nos238. Given that NOS2 inhibi-
tors regress aortic disease in MFS mice19, our data suggest that
the overproduction of NO by NOS2 underlies MFS aortopahy
through sGC–PRKG pathway activation. It therefore seems that
Nos2 activity might overcome the potential positive effects of
Nos3 in MFS aorta.
When uncoupled, NOS2 can lead to overproduction of
superoxide anion and peroxynitrite, which activate many
signaling pathways44,54. NOS2-mediated ROS overproduction
can trigger a positive feedback loop via oxidation of the NOS
cofactor BH455, further uncoupling NOS2 and increasing
superoxide production. In this scenario, high NO and superoxide
anion levels would generate peroxynitrite, leading to nitrosative
stress accompanied by Tyr/Trp-nitration and S-nytrosylation of
proteins and oxidative damage to other biomolecules18. Oxidative
stress has been linked to syndromic and nonsyndromic familial
aortic diseases28,56; moreover, in MFS mice redox stress is asso-
ciated with NOX4 (NADPH oxidase 4), which is upregulated in
the aortas of MFS patients and whose deficiency protects MFS
mice from elastic-fiber fragmentation and aortic dilation28.
Because NO diffuses from the vascular wall to the lumen, the
rise in nitrated proteins in MFS mice and patients indicates
increased NO production in MFS and suggests that, despite the
presence of high ROS levels, NOS2 generates high amounts of
NO in MFS mice and patients. These data are also consistent with
a recent report showing significant elevation of NO-derived
metabolites such as nitrites in the plasma of MFS patients57.
Nitration on Tyr and Trp is considered a stable NO-derived
post-translational modification58, and only a few studies have
reported these modifications in plasma59–61. Given the low
abundance of nitration, its detection in complex samples such as
plasma is challenging with currently available technology, and we
were able to detect Tyr/Trp-nitration only in some abundant
proteins. Nevertheless, our data show that nitration is markedly
upregulated in MFS mice and that MFS mice and NO-treated WT
mice have similar nitration profiles, further supporting the notion
that excessive NO production underlies MFS. Moreover, given the
upregulation of plasma-protein nitration in MFS patients, our
data also suggest that a highly nitrated plasma profile may be a
signature of MFS, warranting future assessment of this post-
translational modification as a biomarker of the disease.
Other markers of MFS identified in our study include cGMP,
whose plasma levels are substantially upregulated in MFS mice
and three MFS patient cohorts. Circulating cGMP appears to be a
good indicator of sGC activity that can be easily determined in
patient plasma or serum. Indeed, elevated cGMP has been
reported in other diseases, including congestive heart failure and
several cancers62–64.
Given that pVASP-S239 appears to be a good marker of PRKG
activity30, its increase in the aortas of MFS patients strongly
suggests enhanced PRKG activity in this tissue. This idea is
supported by the marked drop in pVASP-S239 in MFS VSMCs
treated with the PRKG inhibitor KT5823 and in the aortas of
MFS mice treated with ODQ, KT5823, or lentivirus encoding
Fig. 6 Quantitative proteomics shows that increased protein nitration is a signature of MFS in mice and humans. Quantitative proteomics analysis of
plasma samples from a untreated WT mice (n= 7), MFS mice (n= 7), and DetaNO-treated WT mice (n= 6) and b MFS patients (n= 23) and healthy
donors (n= 30). Data were analyzed using the SanXoT package. Theoretical, normal distribution; Nitro-proteins, cumulative distributions of indicated
nitrated protein values corrected to the values for nonmodified peptides from the same protein; All-proteins, cumulative distributions of nonmodified
peptides. Data are expressed in standardized log2-ratios (Zq) relative to a untreated WT or b healthy donors (Control). Differences were analyzed by two-
tailed Kolmogorov-Smirnov test (p-values are shown; n.s., not significant). Representative annotated fragmentation spectra for 2 mouse nitro-peptides are
provided in Supplementary Fig. 9. All MS/MS spectra of identified tryptic nitro-peptides are provided in the Data availability section. c List of nitrated
peptides showing significantly higher abundance in MFS patients. The heatmap shows standardized log2-ratios (Zpq) and statistical significance calculated
using limma analysis. The annotated fragmentation spectra of these 7 nitro-peptides are provided in Supplementary Fig. 10. d Nitrated plasma index,
defined as the weighted mean of the nitro-peptides listed in c, for 23 MFS patients and 30 healthy donors (Control). Each data point denotes an individual,
boxes enclose the interquartile range (IQR), the line in the box shows the centre (median), and whiskers extend 1.5 times above and below the IQR.
Differences were analyzed by unpaired two-tailed Student’s t-test. e Quantitative proteomics analysis of pooled aortic samples from 12 untreated WT mice
(n= 6 pools) and 12 MFS mice (n= 6 pools). Nitrated protein distributions are shown as in a and b. Differences were analyzed by two-tailed Kolmogorov-
Smirnov test. f Barplots showing standardized log2-ratios (Zq) integrated by condition (untreated WT and MFS) for significantly upregulated nitro-proteins
related to the cytoskeleton: thrombospondin type-1 domain-containing protein 4 (THSD4), coronin 1-C (CORO1C), latent-transforming growth factor beta
2 and 4 (LTBP2, LTBP4), actin aortic smooth muscle (ACTA2), tensin 3 (TNS3), dynein heavy chain 10 (DNAH10), and tubulin beta 4 chain (TUBB4B).
Differences were analyzed by limma statistical analysis (exact p-values are shown). Source data are provided in the Source Data file.
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Prkg1-shRNA. These findings suggest that analysis of pVASP-
S239 in TAAD tissue samples obtained during elective or emer-
gency aortic root surgery could be used to assess the extent of
PRKG activation in these tissues.
Aortic dissection is the major cause of morbidity and mortality
in MFS. Unfortunately, dissection often occurs when the aortic
diameter is below the recommended threshold for elective pro-
phylactic surgery65,66. This is also the case for type B dissections
in MFS patients with prior prophylactic aortic surgery67. The
identification of biomarkers that predict the risk of dissection
would help in surgical decision-making. Plasma cGMP and Tyr/
Trp-nitrated proteins could help to monitor the course of the
disease or the efficacy of future treatments in clinical trials;
however, future studies involving a larger clinical sample will be
needed to support the prognostic potential of plasma cGMP and
protein nitration. It is important to interpret changes in the
identified markers with caution because our comparison of cir-
culating markers was limited to MFS patients and healthy donors.
Upregulated levels of the markers we describe here are likely a
feature of other diseases involving NO pathway activation, such
as infection, inflammation, allergy, or sepsis68,69. Although the
identity of nitrated plasma proteins may differ depending on the
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pathology, these markers would in principle be more suitable for
monitoring or predicting disease course than for diagnosis. Again,
future studies in larger clinical cohorts will be important in
determining whether pharmacological treatment can modify the
profile of nitrated proteins and the levels of cGMP. The presence
of increased plasma cGMP and protein nitration in patients and
MFS mice indicates that medical treatment does not induce this
increase, but it will be important to confirm that medication does
not affect the protein nitration profile. Regardless of their
potential as biomarkers in familial aortopathies, cGMP and
protein nitration appear to be useful tools for determining if this
pathway is also activated in other TAADs.
Tissue levels of pVASP-S239 could also be used to determine if
PRKG activation is a signature of other TAADs. Recent findings
show that a gain-of-function mutation in the human PRKG1 gene
generates a constitutively activated kinase and predisposes to
TAA in affected families; moreover, the equivalent activating
mutation in heterozygous mice (Prkg1R177Q/+ mice) triggers an
age-dependent aortic dilation56,70,71. In affected families, the
increased PRKG1 activity stimulates myosin regulatory light
chain phosphatase, which can alter VSMC contractility71. It is
thus clear that PRKG activation can mediate aortopathy in syn-
dromic and nonsyndromic familial TAAD. It remains to be seen
whether sGC–PRKG pathway activation also mediates disease in
syndromic diseases other than MFS or in nonsyndromic TAADs
not caused by PRKG1 mutation.
An essential role of NO–sGC–PRKG signaling in aortopathy
does not exclude roles in the disease for NOS2-derived signals
independent of this pathway. Indeed, oxidants such as NOS2-
derived superoxide anion can also activate PRKG29, and signals
downstream of PRKG involving oxidative stress and JNK acti-
vation have been shown to mediate aortopathy in Prkg1R177Q/+
mice, in which antioxidants prevent age-dependent aortic
dilation56. However, the action of PRKG appears to be mediated
mainly through its regulation of contractility via myosin light
chain phosphatase activation and decreased calcium influx in
VSMCs44,72. The drop in cellular calcium levels might contribute
to aortic disease, as suggested by the deleterious effect of calcium
channel blockers (CCBs) in MFS mice and by the increased risk
of aortic dissection and need for aortic surgery in MFS patients
treated with CCBs compared with patients receiving other anti-
hypertensive drugs73. Indeed, the aortic damage caused by CCBs
in MFS might be attributable to its cooperation with PRKG
activation in depleting cellular calcium stocks. Guideline recom-
mendations for CCBs as an alternative blood pressure regulator in
patients at risk of aortic aneurysm should perhaps be revisited.
Our data showing VASP-mediated modulation of actin fiber
formation suggest that PRKG regulation of contractility might be
regulated not only through the myosin components of the acto-
myosin cytoskeleton, but also through actin. Since actin Tyr
nitration impairs actin polymerization dynamics74, our finding
that numerous Acta2 Tyr residues are nitrated in the aortas of
MFS mice reveals an additional mechanism for NO-mediated
regulation of actomyosin cytoskeleton dynamics tuning and for
contractility dysregulation. In this scenario, the induction of
contractility markers might be seen as an adaptative response to a
deficient capacity of the aorta for contraction.
Our results suggest that the control of NO levels and signaling
in the aorta is critical for VSMC homeostasis and implicate
abnormally high NO–sGC–PRKG signaling as the underlying
cause of aortopathy in MFS mice and patients. PRKG can be
activated by superoxide anion; however, our data showing that
sGC pharmacological inhibition reduces pVASP-S239 in vitro
and in vivo strongly suggest that PRKG activation in MFS is
dependent on sGC activity. Furthermore, the regression of aortic
dilation in MFS mice treated with ODQ supports a causal role for
sGC activation in the disease. Similarly, the reversion of aortic
dilation and medial degeneration in MFS mice treated with PRKG
inhibitors or aortic Prkg1 knockdown also strongly suggests that
MFS is mediated by PRKG activation.
Although prophylactic surgery has increased the lifespan of
MFS patients, there are currently no pharmacological treatments
able to arrest aortic growth or prevent dissections14,75. There is
therefore an urgent need to develop effective therapies. Our data
lay the basis for exploring the implication of NO–sGC–PRKG
signaling in other forms of TAAD and determining the potential
of sGC or PKRG inhibition in the treatment of patients with MFS
or other forms of TAAD.
Methods
Animal procedures. Animal procedures and experiments complied with all rele-
vant ethical regulations, were approved by the CNIC Ethics Committee and the
Madrid regional authorities (ref. PROEX 80/16) and conformed to EU Directive
2010/63EU and Recommendation 2007/526/EC regarding the protection of ani-
mals used for experimental and other scientific purposes, enforced in Spanish law
under Real Decreto 1201/2005. Overall mouse health was assessed by daily
inspection for signs of discomfort, weight loss, or changes in behavior, mobility,
and feeding or drinking habits. Mice were housed in a pathogen-free animal facility
under a 12 h light/dark cycle at constant temperature and humidity, and fed
standard rodent chow and water ad libitum. Fbn1C1039G/+ mice33, which harbor a
mutation in the Fbn1 gene, were obtained from Jackson Laboratories (JAX mice
stock #012885). This strain had been previously backcrossed to the C57BL/6
Fig. 7 Pharmacological inhibition of sGC or PRKG reverts aortopathy in Marfan syndrome. a Experimental design. 14-week-old MFS mice were treated
daily for 21 days with 20mg/kg/day ODQ. Longitudinal ultrasound and BP analysis (Eco-BP) was performed at the indicated times (empty triangles).
b Plasma cGMP at 21 d (n= 8WT mice, n= 10 MFS mice, and n= 9 ODQ-treated MFS mice). c Representative pVASP-S239 immunofluorescence (red) in
mouse aortic sections. Yellow dashed lines delineate the lumen boundary. IgG staining served as a negative control. Scale bar, 50 µm. d Quantification of
pVASP-S239 immunofluorescence in aortic sections from 10 untreated WT mice (−), 10 MFS mice, and 9 MFS mice treated with 20mg/kg/day ODQ for
21 d. IgG staining served as a negative control. Scale bar, 50 µm. b, d Data are mean ± s.e.m. Each data point denotes an individual mouse. Differences were
analyzed by one-way ANOVA with Tukey’s post-hoc test (p-values are shown). e, f Systolic BP (e) and maximal AsAo and AbAo (f) diameter at the
indicated times (n= 5 mice each for untreated and ODQ-treated MFS groups; n= 7 mice for WT group). Data are mean ± s.e.m. **P < 0.01, ***P < 0.001,
and ****P < 0.0001 (versus WT mice); ##P < 0.01, ###P < 0.001, and ####P < 0.0001 (versus untreated MFS) by repeated-measurements two-way
ANOVA with Tukey’s post-hoc test. g Experimental design. 14-week-old MFS mice were treated daily for 7 days with 2 µmol/kg/day KT5823 and
monitored for aortic dilation and BP before treatment and 3 d and 7 d post-treatment. h Representative pVASP-S239 immunofluorescence (red) in mouse
aortic sections. Yellow dashed lines delineate the lumen boundary. IgG staining served as a negative control. Scale bar, 50 µm. i Quantification of pVASP-
S239 immunofluorescence in aortic sections from untreated WT mice (−) (n= 5), MFS mice (n= 5), and MFS mice treated with 2 µmol /kg/day KT5823
for 7 d (n= 7). Data are shown relative to untreated WT mice as mean ± s.e.m. Each data point denotes an individual mouse. Differences were analyzed by
one-way ANOVA with Tukey’s post-hoc test (p-values are shown). j, k Systolic BP (j) and maximal AsAo and AbAo (k) diameter at the indicated times (n
= 10 for untreated WT group; n= 8 per each MFS group). Data are mean ± s.e.m. ***P < 0.001 and ****P < 0.0001 (versus WT), #P < 0.05 and ##P < 0.01
(versus untreated MFS) by repeated-measurements two-way ANOVA with Tukey’s post-hoc test. Source are provided in the Source Data file.
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background for more than nine generations. All mice were genotyped by tail-
sample PCR using the following primers: 5′-CTCATCATTTTTGGCCAGTTG-3′
and 5′−GCACTTGATGCACATTCACA-3′. Wild-type (WT) mice were on the
C57BL/6 background, and 12–15-week-old males and females were used for all
experiments. Mice were treated with isosorbide mononitrate (ISMN; MedChem
Express; Monmouth Junction, NJ, USA) or DetaNONOate (DetaNO; Enzo Life
Sciences; Farmingdale, NY, USA) using subcutaneous osmotic minipumps (Alzet
Corp; Cupertino, CA, USA). The specific inhibitors of sGC (ODQ) and PRKG
(KT5823), both from Focus Biomolecules (Plymouth Meeting, PA, USA), were
dissolved in dimethylsulfoxide (DMSO), diluted in 0.9% NaCl (DMSO content was
<0.5%), and administered i.p. at 20 mg/kg/day for 21 days and 5 mg/kg/day for
7 days, respectively. Control mice received the corresponding intraperitoneal
vehicle.
Blood pressure measurements. Arterial blood pressure (BP) was measured in
mouse tails using the automated BP-2000 Blood Pressure Analysis System and
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-22933-3 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:2628 | https://doi.org/10.1038/s41467-021-22933-3 | www.nature.com/naturecommunications 13
software (Visitech Systems, Apex, NC, USA)32,76. BP measurements were recorded
in mice located in a tail-cuff restrainer over a warmed surface (37 °C). Mice
underwent a training period, with BP monitored every day for 7 days. After that,
baseline BP was measured 1 day before the beginning of the treatment in each
mouse cohort. Fifteen consecutive systolic BP measurements were made, and the
last 10 readings per mouse were recorded, tested for outliers using the Chauvenet’s
criterion and averaged. BP monitoring was repeated during experiments as indi-
cated in the Figure legends.
In vivo ultrasound imaging. Images of the aorta were obtained in isoflurane-
sedated mice (2% isoflurane) by high-frequency ultrasound with a VEVO 2100
echography device (Fujifilm-VisualSonics, Toronto, Canada) with a transducer that
provides 30-micron axial resolution. Maximal internal aortic diameters were
measured at systole using VEVO 2100 software, version 1.5.0 (VisualSonics).
Measurements were taken before treatment initiation to determine the baseline
diameters and were repeated several times during the experiment.
Cell procedures. Primary mouse vascular smooth muscle cells (VSMCs) were
isolated from 4–6-week-old mice and grown as described31,32. Briefly, tissue was
digested with a solution of collagenase and elastase until a single-cell suspension
was obtained. Cells were then cultured at 37 °C, 5% CO2 in growth medium
(Dulbecco’s modified Eagle’s medium [DMEM)] supplemented with 20% fetal
bovine serum [FBS]). All experiments were performed during passages 3–7.
VSMCs were FBS-starved 36 h before stimulation experiments. The HEK-293T
(CRL-1573) and Jurkat (Clone E6-1, TIB-152) cell lines, required for high-titer
lentivirus production and lentivirus titration, respectively, were purchased from
ATCC. All cells were mycoplasma-negative.
VSMCs were incubated with 100µM DetaNO or 100 µM 8-bromo-guanosine
3',5'-cyclic monophosphate (8-Br-cGMP; Biolog; Bremen, Germany). In some
experiments, the NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME, 300
µM; Sigma–Aldrich; St. Louis, MO, USA), ODQ (10 µM), or KT5823 (1 µM), were
added to VSMCs 1 h before the addition of DetaNO or 8-Br-cGMP. In another set
of experiments, MFS VSMCs were incubated for 24 h with KT5823.
For cell immunostaining, cells were fixed with 4% paraformaldehyde for 10 min
and permeabilized with 0.3% Triton X-100 in PBS for 30 min. Samples were
incubated overnight with anti-phospho-VASP (1:50, sc-101439; Santa Cruz
Biotechnology; Santa Cruz, CA, USA) or rabbit anti-fibrillin-1 polyclonal
antibody77 (1:2000, pAb9543; kindly donated by Dr. L. Sakai). The secondary
antibody was AlexaFluor568-conjugated goat anti-mouse (1:500; A-11031;
Molecular Probes; Carlsbad, CA, USA). To determine F-actin formation, cells were
stained with Texas Red-X-conjugated phalloidin (1:2000, T7471; Thermo Fisher
Scientific, Bremen, Germany) in at least three independent batches, with three
technical triplicates per condition and batch and at least three images captured per
triplicate. Images were acquired at 1024 × 1024 pixels, 8 bits, using a Confocal TCS
Leica SP5 microscope (Leica Microsystems GmbH; Wetzlar, Germany) fitted with a
×40 oil-immersion objective and Leica LAS-AF V2.7.3. acquisition software. All
images were processed for presentation with Photoshop (Adobe) according to the
guidelines of this journal and analyzed with ImageJ software (version 1.52a, NIH,
http://rsb.info.nih/ij/). Staining was quantified after setting an intensity threshold
to include only specific signals. For intracellular staining, total intensity was
relativized to cell area. For extracellular staining of Fbn1, the signal was calculated
as the stained area. Each condition’s value was relativized to the average staining of
the experiment.
Lentivirus production and infection. A lentiviral plasmid encoding GFP and
shRNA targeting mouse Prkg1 was engineered by cloning the following shRNAs
into the pH1-DUAL lentiviral vector: shPrkg1-A (sense) 5′- GATCCCCTTGCTTT
GCTCTGATTATACTCGAGTATAATCAGAGCAA AGCAAGGTTTTTTGC-3′;
shPrkg1-A (antisense) 5′- GGCCGCAAAAAACCTTGC TTTGCTCTGATTATAC
TCGAGTATAATCAGAGCAAAGCAAGGg-3′; shPrkg1-B (sense) 5′- GATCCCC
GGAGAATCTCATCCTAGATCTCGAGATCTAGGATGAGA TTCTCCGGTTT
TTGC-3′; shPrkg1-B (antisense) 5′- GGCCGCAAAAACCGGAGAA TCTCATCC
TAGATCTCGGATCTAGGATGAGATTCTCCGGG. Pseudo-typed lentiviruses
were produced by transient calcium phosphate transfection of HEK-293T cells with
a plasmid encoding GFP and Prkg1-specific shRNA. Viruses were concentrated
from culture supernatant by ultracentrifugation (2 h at 121,896xg; Ultraclear
Tubes; SW28 rotor and Optima L-100 XP Ultracentrifuge; Beckman, Brea, CA,
USA), suspended in cold sterile PBS, and titrated by infection of Jurkat cells. Jurkat
cells were seeded in a 96-well plate and infected with the desired lentiviral dilution
(1:10-1:100000). After 48 h, cells were centrifuged 5 min at 1800 × g and resus-
pended in 200 microL of ice-cold PBS with 1:1000 propidium iodide. Transduction
efficiency (% of GFP-expressing cells) and cell death (propidium iodide incor-
poration) were quantified by flow cytometry, as illustrated in Supplementary
Fig. 14. Flow cytometry data were collected using a Canto 3L HTS cytometer and
the BD FACSDiva Software Version 6.1.3, and analyzed using FlowJo
10.7.1 software.
VSMCs were infected (multiplicity of infection= 10) overnight at 37 °C in
growth medium. Medium was then replaced with fresh growth medium, and cells
were cultured for 7 additional days and then processed for mRNA expression
analysis and cell immunostaining or stimulated for 5 min with DetaNO for
immunoblot assays. For in vivo transduction experiments, animals were
anesthetized (with ketamine and xylazine), and a small incision was made to
expose the right jugular vein49. Virus solution (100 μl, 109 particles/ml in PBS) was
injected directly into the right jugular vein. Transduction efficiency was analyzed in
aortic samples by GFP immunohistochemistry and PRKG immunofluorescence.
cGMP immunoassay. cGMP was measured in mouse and human plasma by
competitive enzyme immunoassay (KGE003, R&D Systems; Minneapolis, MN,
USA). To obtain mouse plasma, blood was extracted after sacrifice by CO2 inha-
lation using the cardiac puncture method, collected in EDTA tubes, and cen-
trifuged for 15 min at 13,000 × g. Plasma and serum samples from MFS patients
and healthy blood donors were obtained and processed following standard oper-
ating procedures.
Histology. After sacrifice of mice by CO2 inhalation, aortas were perfused with
saline, isolated, fixed in 10% formalin overnight at 4 °C, and paraffin embedded.
Paraffin cross-sections (5 μm) from fixed ascending aortas (AsAo) were prepared
for immunochemistry or immunofluorescence, or stained with hematoxylin and
eosin, Alcian blue, or modified Verhoeff elastic-Van Gieson (EVG) kit
(Sigma–Aldrich). Images were acquired under a Leica DM2500 microscope fitted
with a ×40 HCX PL Fluotar objective or with a scanner NanoZoomer-2.
ORSC110730. Leica Application Suite V3.5.0 acquisition software and NDP.view 2
V2.7.43 software were used, respectively. Elastic lamina breaks, defined as inter-
ruptions in elastic fibers, were counted in the entire medial layer of six non-
consecutive cross-sections per mouse, using 4–12 mice per experiment. The mean
number of breaks was calculated. The exact number of mice per group is indicated
in the figure legends.
Fig. 8 Prkg1 silencing reverts aortopathy in Marfan syndrome. a Representative immunoblot analysis (n= 2 independent experiments) of Prkg1
expression in WT DetaNO-treated VSMCs transduced with lentivirus (LVi) encoding control shRNA (shScr) or Prkg1-specific shRNAs A, B, and C.
Uncropped blots in Supplementary Fig. 13. b Experimental design; 14-week-old MFS mice were inoculated through the jugular vein with LVi encoding GFP
and either a control shRNA (shScr) or Prkg1-specific shRNAs A and B. Mice were monitored for aortic dilation and BP prior to treatment and at the
indicated times. c Representative images of GFP immunohistochemistry (top) and Prkg1 immunofluorescence (bottom). Top and bottom yellow dashed
lines delineate the lumen and the adventitia boundary, respectively. IgG staining of AsAo sections from shScr-transduced MFS mice served as a negative
control. Scale bar, 50 µm. d Quantification of Prkg1 immunofluorescence in AsAo sections of control WT and shScr-, and shPrkg1-B-transduced MFS mice
(n= 9 in WT mice and MFS mice infected with shPrkg1-B, n= 10 in MFS mice infected with shScr or Prkg1-A). Data are shown relative to WT mice as mean
± s.e.m. Each data point denotes an individual mouse. e Representative pVASP-S239 immunofluorescence (red) in mouse aortic sections. Yellow dashed
lines delineate the lumen boundary. IgG staining served as a negative control. Scale bar, 50 µm. f Quantification of pVASP-S239 immunofluorescence in
aortic sections from 9 WT, 8 MFS shScr, 10 MFS shPrkg1-A, and 9 MFS shPrkg1-B mice. Data are shown relative to uninfected WT mice as mean ± s.e.m.
Each data point denotes an individual mouse. d, f Differences were analyzed by one-way ANOVA with Tukey’s post-hoc test (p-values are shown). g, h
Maximal AsAo and AbAo (g) diameter and systolic BP (h) at the indicated times (n= 10 per group). Data are mean ± s.e.m. *P < 0.05, **P < 0.01, ***P <
0.001, and ****P < 0.0001 versus shScr by repeated-measurements two-way ANOVA with Tukey’s post-hoc test. i Representative images showing staining
with hematoxylin and eosin (HE) and elastic van Gieson (EVG) in AsAo of the indicated mice (n= 9–10 mice per group). Yellow arrowheads indicate
elastin breaks. Scale bar, 50 μm. j Wall thickness and k elastin breaks in AsAo sections from the mouse cohorts shown in i. Data are mean ± s.e.m. Each
data point denotes an individual mouse. j, k Differences were analyzed by one-way ANOVA with Tukey’s post-hoc test (p-values are shown). Source data
are provided in the Source Data file.
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For immunofluorescence, deparaffinized sections were rehydrated, boiled 3 min
to retrieve antigens in 10 mM citrate buffer containing 0.05% Tween-20, pH6, and
blocked for 1 h with 10% goat serum plus 2% BSA in PBS. Samples were incubated
with the following antibodies for immunohistochemistry or immunofluorescence:
mouse monoclonal anti-pVASP (1:50; sc-101439, Santa Cruz Biotechnology, Santa
Cruz, CA, USA), rabbit polyclonal anti-p-VASP (1:25; SAB4300129,
Sigma–Aldrich, St. Louis, MO, USA), rabbit polyclonal anti-PRKG (1:50, ADI-
KAP-PK005-F, Enzo Life Sciences), and rabbit polyclonal anti-GFP (1:100,
A11122, Invitrogen; Carlsbad, CA, USA). Specificity was determined by
substituting the primary antibody with unrelated IgG (Santa Cruz) at the same
dilutions as the antigen-specific antibodies. For immunohistochemistry, color was
developed with DAB (Vector Laboratories; Burlingame, CA, USA), and sections
were counterstained with hematoxylin and mounted in DPX (Casa Álvarez,
Madrid, Spain). For immunofluorescence, secondary antibodies were polyclonal
Alexa-Fluor-647-conjugated goat anti-rabbit or polyclonal Alexa-Fluor-647-
conjugated chicken anti-mouse (1:500, Molecular Probes). Sections were mounted
with DAPI in Citifluor AF4 mounting medium (Aname; Madrid, Spain). For
immunofluorescence and immunohistochemistry in mouse and human aortic
tissue, antibody staining was quantified in the medial layer of three nonconsecutive
whole cross-sections per aorta, using 4–12 aortas per condition. The rare
histological preparations excluded were those lacking a whole aortic cross-section.
The whole aortic cross-section was screened before taking representative pictures
(minimum of three). Immunostaining was technically validated with samples from
the same experimental unit in three independent experiments. Images were
acquired at 1024 × 1024 pixels, 8 bits, using a Confocal TCS Leica SP5 microscope
(Leica Microsystems GmbH; Wetzlar, Germany) fitted with a 40x oil-immersion
objective.
All images were processed for presentation with Photoshop (Adobe) according
to the guidelines of this journal and analyzed with ImageJ software (version 1.52a,
NIH, http://rsb.info.nih/ij/).
Real-time and quantitative PCR. Total RNA was isolated from VSMCs or from
aortas by homogenization with TRIzol (Invitrogen; Carlsbad, CA, USA). Total
RNA (2 μg) was reverse-transcribed at 37 °C for 50 min in a 20-μl reaction mix
containing 200 U Moloney murine leukemia virus (MMLV) reverse transcriptase
(Promega; Madison, Wi, USA), 100 ng random primers and 40 U RNase Inhibitor
(Invitrogen). The sequences of the sense and antisense primers used for amplifi-
cation are described in Supplementary Table 1. qPCR reactions were performed in
triplicate with SYBR master mix (Promega) according to manufacturer guidelines.
Probe specificity was assessed in a post-amplification melting-curve analysis. For
each reaction, only one melting-temperature (Tm) peak was produced. The
amount of target mRNA in samples was estimated by the 2−ΔCT relative quanti-
fication method, using Gapdh for normalization. Fold ratios were calculated rela-
tive to mRNA expression levels from control animals. qPCR data were analyzed
using the Bio-Rad CFX Manager 3.1 software and further analysis was performed
in Excel software.
Immunoblot analysis. Samples from mouse aortas were isolated, frozen in liquid
nitrogen and then homogenized (MagNA lyzer, Roche). VSMCs were washed with
ice-cold PBS and lysed in ice-cold total lysis buffer (20 mM Tris‐HCl, pH 7.5; 1%
Triton X‐100; 50 mM NaF; 5 mM MgCl2; 500 mM NaCl; 10 mM EDTA) supple-
mented with protease, phosphatase, and kinase inhibitors (100 μM benzamidin, 1
μg/ml leupeptin, 1 μg/ml pepstatin, 1 μg/ml aprotinin, 1 μM ditiotreitol, 1 mM
PMSF, and 3 mM EGTA). Proteins were separated under reducing conditions on
SDS–polyacrylamide gels, transferred to nitrocellulose membranes, and detected
with rabbit polyclonal anti-PRKG1 (1:1000, ADI-KAP-PK005-F, Enzo Life Sci-
ences), anti-Gapdh (1:10,000; ab8245 Abcam, Cambridge, UK), rabbit polyclonal
anti-GUCY1A3 (1:1000, 12605-1-AP; Proteintech, Rosemont, IL, USA), rabbit
polyclonal anti-GUCY1B3 GUCY1A3 (1:500, 19011-1-AP; Proteintech), and
mouse monoclonal anti-α-Tubulin (1:40,000, T 6074; Sigma–Aldrich, St. Louis,
MO, USA). Bound antibodies were detected with enhanced-chemiluminescence
(ECL) detection reagent (Millipore, Darmstadt, Germany). All uncropped blots are
presented in Supplementary Fig. 13.
Human samples. The study complies with all relevant ethical regulations and was
approved by the Research Ethics Committee of Cantabria (ref. 27/2013), the Ethics
Committee of Ghent University Hospital (B65020111160), and the Ethics Com-
mittee of Instituto de Salud Carlos III (CEI PI91_2018-v2-Enmienda_2019). Aorta,
plasma and serum samples from patients with Marfan Syndrome were obtained
from biobanks of Hospital Puerta de Hierro, Hospital Vall D’Hebron, and Ghent
University Hospital. Tissue samples from MFS patients were obtained during
elective or emergency surgery for aortic root replacement. Age- and sex-matched
ascending aorta samples used as controls were obtained anonymously from mul-
tiorgan transplant donors. During preparation of the heart for transplantation,
excess AsAo tissue was trimmed and harvested for the study. Tissues were
immediately fixed, kept at room temperature for 48 h, and embedded in paraffin.
Age- and sex-matched control plasma samples were obtained from healthy
volunteers. Informed consent was obtained from all human participants or their
families. Patient clinical data were retrieved while maintaining anonymity.
Proteomics. Nitration of plasma and ascending aorta proteins was assessed by
high-throughput multiplexed isobaric labeling analysis in control and DetaNO-
treated C57BL/6 WT mice and MFS mice. In the plasma experiment, seven control,
six DetaNO-treated, and seven MFS animals were used, whereas in the aorta
experiment each group of WT and MFS animals consisted of six pools of two
biological replicates (a total of 24 animals). In both experiments, samples were
analyzed in two TMT 10-plex batches, each containing three or four biological
replicates from each experimental condition. In the aorta experiment, two channels
were reserved for internal reference standards created by pooling the WT peptide
samples. Proteins were extracted from AsAo (50 mg per pool) by tissue homo-
genization with ceramic beads (MagNa Lyser Green Beads, Roche, Germany) in
extraction buffer (100 mM Tris-HCl pH 7.4, 1 mM EDTA, 4% SDS). Plasma
proteins (200 µg per animal) were obtained from about 4 µl plasma, which was
mixed with the same volume of 50 mM Tris, 2% SDS, and 50 mM DTT. In both
experiments, proteins were denatured by boiling for 5 min and subjected to filter-
aided digestion (Nanosep Centrifugal Devices with Omega Membrane-10K,
PALL)78. Briefly, urea was added to each sample to bring SDS concentration down
to 0.06%. Samples were then transferred to the filter and centrifuged at 14,000 × g
for 10 min. Cys residues were blocked with 50 mM iodoacetamide for 1 h at room
temperature in the dark. After three washes with 100 µl 50 mM ammonium
bicarbonate pH 8.8, proteins were digested with trypsin (1:30 trypsin:protein,
Promega) overnight at 37 °C. After protein digestion, peptides were eluted from the
filter in two steps, first with 40 µl 0.5M ammonium bicarbonate and then with 50 µl
0.5M NaCl. Peptides were acidified with trifluoroacetic acid to a final concentration
of 1%, desalted on C18 Oasis HLB cartridges (Waters, Milford, MA, USA), and
vacuum-dried. Peptides were TMT-labeled according to the manufacturer’s
instructions and desalted on OASIS extraction cartridges. Plasma peptides were
separated into four fractions with increasing amounts of acetonitrile (Fr1, 15%; Fr2,
17.5%; Fr3, 20%; and Fr4, 50%), whereas the aorta peptides where separated into
five fractions (Fr1, 12.5%; Fr2, 15%; Fr3, 17.5%; Fr4, 20%; and Fr5, 50%) using the
high pH reversed-phase peptide fractionation kit (Thermo Fisher Scientific, Bre-
men, Germany), and dried-down before MS analysis.
Quantitative proteomics using multiplexed isobaric labeling was also used to
analyze nitration of plasma proteins from 30 healthy donors and 23 MFS patients.
Samples were analyzed in seven TMT batches. Each TMT batch contained plasma
samples from each of the two experimental conditions and two channels were
reserved for reference internal standards created by pooling the control peptide
samples. Protein digestion and TMT labeling and fractionation of peptides were
performed as described above, using five fractions with increasing amounts of
acetonitrile.
Each fraction of the labeled peptide samples was analyzed using a Proxeon Easy
nano-flow HPLC system (Thermo Fisher Scientific) coupled via a nanoelectrospray
ion source (Thermo Fisher Scientific) to either a Q-Exactive HF mass spectrometer
(Termo Fisher Scientific) or an Orbitrap Fusion mass spectrometer (Thermo Fisher
Scientific). A C18-based reverse phase separation was used, with a 2-cm trap
column and a 50-cm analytical column (75 µm I.D, 2 µm particle size, Acclaim
PepMap RSLC, 100 C18; Thermo Fisher Scientific). Peptides were loaded in buffer
A (0.1% formic acid in water (v/v)) and eluted with an acetonitrile gradient
consisting of 0–30% buffer B (80% acetonitrile, 0.1% formic acid) for 300 min and
50–90% B for 3 min at a flow rate of 200 nl/min. Mass spectra were acquired in a
data-dependent manner, with an automatic switch between MS and MS/MS using
a top-15 acquisiton method with dynamic exclusion. MS spectra were acquired
with a mass range of 400–1500m/z and 120,000 FT resolution. HCD fragmentation
was performed at 30% normalized collision energy, and MS/MS spectra were
analyzed at 30,000 resolution in the orbitrap. Proteins were identified with the
SEQUEST HT algorithm integrated in Proteome Discoverer 2.1 (Thermo Fisher
Scientific) against a mouse or a human database. The mouse reference proteome
database (UniProtKB/Swiss-Prot and TrEMBL December_2016) was
supplemented with 116 CRAP proteins (Global Proteome Machine)
(50915 sequences) and was concatenated with the inverted database constructed
from the same target databases (101830 sequences in total) using DecoyPYrat79.
The human reference proteome database (UniProtKB/Swiss-Prot July_2018) was
concatenated with the corresponding inverted database following the same
approach (81632 sequences in total). For database searching, parameters were
selected as follows: trypsin digestion with two maximum missed cleavage sites,
precursor mass tolerance of 2 Da, and a fragment mass tolerance of 30 ppm. Met
oxidation (15.994915 Da), Trp-nitration (44.985078 Da), and Tyr nitration
(44.985078 Da) were set as variable modifications. Fixed modifications were
57.021464 Da in Cys and 229.162932 Da in Lys and in the peptide N-terminal
position. The false discovery rate (FDR) was calculated based on the search of
results against the corresponding decoy database using the refined method80 with
an additional filter for precursor mass tolerance of 15 ppm81 and estimation of the
corrected Xcorr82. An FDR of 1% was used as the criterion for peptide
identification.
Quantitative information from TMT reporter intensities was integrated from
the spectrum level to the peptide level and then to the protein level based on the
WSPP model83,84 using the GIA integration algorithm85. Quantitative results were
expressed as log2(Ai/C), where Ai is the intensity of the TMT reporter of the
corresponding sample i and C is the mean intensity of the TMT reporters from the
controls (for mouse plasma samples) or the mean value of the two internal
reference standards (for human plasma or mouse aorta samples). The algorithm
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was modified to incorporate the quantitative values of modified peptides as part of
the automated workflow85–87. Hence, quantitative peptide values are referred to the
weighted averages of the nonmodified peptides from the same protein and are
therefore not affected by protein abundance changes. This statistical model
accurately describes the error distribution of abundance changes for both
nonmodified and modified peptides in null-hypothesis experiments86,87. Peptide
quantifications from the animals in the same group were further integrated to
obtain an averaged value per condition using the GIA algorithm83. Nitro-protein
abundance is calculated as a weighted average of all quantified nitrated peptides,
which as commented above, are referred to the weighted averages of the
nonmodified peptides of the same protein. Relative changes in peptide and protein
abundance (log2-ratios) were expressed in standardized units (Zpq and Zq)83.
Cumulative distributions from two conditions were judged statistically different
according to the two-tailed Kolmogorov-Smirnov test. For human samples,
abundance differences of nitrated peptides between healthy individuals and MFS
patients were analyzed using limma88. Plasma-protein nitration in each patient was
measured as the nitrated plasma index (NPI), defined as the weighted mean of
seven most upregulated nitro-peptides. The statistical difference between mean
NPI values for healthy donors and MFS patients was calculated by unpaired two-
tailed Student’s t-test. For mouse aorta samples, abundance differences in nitro-
proteins between untreated WT and MFS mice were also analyzed by limma
workflow. All tryptic nitrated sequences were annotated in silico by extracting
information from the following databases: Swiss-prot, TrEMBL, Nucleotide
database and PDB. The assignation of leucine and isoleucine residues in nitrated
peptides to the corresponding protein sequences was checked manually.
Statistical analysis. Statistical comparisons were carried out with GraphPad
Prism software 7.05. Appropriate tests were chosen according to the data dis-
tribution. Differences were analyzed by the Student or the Welch t-test (depending
on the variance of the tested conditions after F-test); one-way, two-way or
repeated-measurement two-way analysis of variance (ANOVA); and Bonferroni,
Sidack, Tukey, Dunnett, or Newman post-hoc tests (experiments with ≥3 groups),
as appropriate (variance equality was checked by the Bartlett test). The D´Agos-
tino-Pearson and Shapiro-Wilk normality tests were applied before assuming
normality distribution of the data. Statistical methodology corresponding to pro-
teomics analysis is described above. Statistical significance was assigned at *P <
0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
Sample size was chosen empirically based on our previous experience in the
calculation of experimental variability. The initial estimation of sample size was
made by using software Gpower3.1.94. After this estimation, the initial number of
animals was reduced based on the results obtained from previous experiments. No
data were excluded. The numbers of animals used are described in the
corresponding figure legends. All experiments were performed with at least three
biological replicates, and all attempts on replication were successful. No
randomization was performed to allocate animals into experimental groups, and
investigators were not blinded to group allocation during in vivo experiments.
Experimental groups were balanced in terms of animal age, weight and AsAo/
AbAo basal diameter. Male mice were used throughout the manuscript, except for
experiments corresponding to Fig. 7, where male and female mice were used.
Animals were genotyped before experiments, and they were all caged together and
treated in the same way.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Source data are provided with this paper for all figures. The mass spectrometry raw data
that support the findings of this study, including nitrated peptide MS/MS spectra
(Supplementary Data 2 and 4), mouse reference proteome database December 2016 and
human reference proteome database July 2018, are publicly available in the Peptide Atlas
repository (http://www.peptideatlas.org/PASS/PASS01528). The following databases
were used: UniProtKB, Swiss-Prot and TrEMBL (https://www.uniprot.org/uniprot/),
Nucleotide database (https://www.ncbi.nlm.nih.gov/nucleotide/), Protein Data Bank,
PDB (https://www.rcsb.org/). Other relevant datasets generated and/or analyzed during
the current study are available from the corresponding authors on reasonable
request. Source data are provided with this paper.
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